Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2012
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
G04BD12
|
| gptkbp:contraindication |
severe uncontrolled hypertension
|
| gptkbp:drugClass |
beta-3 adrenergic agonist
|
| gptkbp:eliminationHalfLife |
50 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:form |
extended-release tablet
|
| gptkbp:genericName |
gptkb:mirabegron
|
| https://www.w3.org/2000/01/rdf-schema#label |
Myrbetriq
|
| gptkbp:manufacturer |
gptkb:Astellas_Pharma
|
| gptkbp:mechanismOfAction |
relaxes detrusor smooth muscle
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
constipation
headache hypertension urinary tract infection nasopharyngitis |
| gptkbp:usedFor |
urinary incontinence
overactive bladder urinary frequency urinary urgency |
| gptkbp:bfsParent |
gptkb:mirabegron
gptkb:Astellas_Pharma_Inc. |
| gptkbp:bfsLayer |
7
|